Dr. Vlock on Anti–CD20 Interleukin-2 Immunocytokine in NHL Daniel R. Vlock, MD, founder and CEO, Alopexx Enterprises, discusses a phase I/II study of an anti–CD20 interleukin-2 immunocytokine in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Read more here.
Tag: alopexx
Dr. Pier in Sporting News
Daniel Fells’ MRSA battle a chilling reminder of infection danger in NFL One can only wonder about the amount of outrage (mixed with a heavy dose of despair) swirling around the mind of Daniel Fells, who remains hospitalized after multiple combative surgeries against a staph infection. Read more here.
Alopexx work is cited
This new approach could be a solution to our superbug crisis Drug-resistant bacteria, commonly known as superbugs, are making public health officials nervous, and a team of scientists from Brigham and Women’s Hospital think they may have two possible solutions to the problem: vaccines and antibodies designed to take on not just one superbug, but […]